Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * Akero
To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of Directors
09:19pm, Monday, 06'th Jul 2020
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) - André Choulika, Ph.D., Cellectis’ Chairman and CEO, announces that he will focus all his energy on Cellectis’ development activities, and thus,
Cellectis Reports Clinical Hold Placed on MELANI-01 Study
08:33pm, Monday, 06'th Jul 2020
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELAN
Cellectis SA (CLLS): Hedge Funds Are Snapping Up
02:28am, Monday, 06'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?
03:30pm, Tuesday, 30'th Jun 2020
Is (CLLS) Outperforming Other Medical Stocks This Year?
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 29, 2020
08:30pm, Monday, 29'th Jun 2020
NEW YORK, June 29, 2020 -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 29, 2020 at its head office in Paris,.
Cellectis Starting To Look Like A Biotech Buy
01:35pm, Monday, 29'th Jun 2020
Cellectis has shown promise in its oncology treatment and a new paper shows that it's able to overcome early risk detection. A new chief medical officer signing
Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies
08:30pm, Thursday, 25'th Jun 2020
NEW YORK, June 25, 2020 -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic.
Monthly information on share capital and company voting rights
08:30pm, Wednesday, 10'th Jun 2020
NEW YORK, June 10, 2020 -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting.
Moving Average Crossover Alert: Cellectis
01:05pm, Monday, 08'th Jun 2020
Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?
03:30pm, Wednesday, 03'rd Jun 2020
Is (CLLS) Outperforming Other Medical Stocks This Year?
Cellectis' Shares March Higher, Can It Continue?
11:56am, Monday, 01'st Jun 2020
As of late, it has definitely been a great time to be an investor in Cellectis.
Cellectis Appoints Biopharma Veteran Leopold Bertea as Senior Vice President of Technical Operations - Europe
08:30pm, Monday, 18'th May 2020
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced
How Cellectis (CLLS) Stock Stands Out in a Strong Industry
01:08pm, Wednesday, 13'th May 2020
Cellectis (CLLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 12th
02:02pm, Tuesday, 12'th May 2020
Top Ranked Momentum Stocks to Buy for May 12th
